AstraZeneca's (AZN) Presents Data for BRILINTA Used in Patients in with ACS

AstraZeneca's (NYSE: AZN) announces that an endpoint was maintained in Acute Coronary Syndromes (ACS) patients who received the investigational oral antiplatelet treatment, ticagrelor (BRILINTA), were maintained, whether or not they had the genetic variability that has been previously shown to affect a patient's response to clopidogrel. The substudy is the first to look at both efficacy and bleeding endpoints of ACS patients treated with ticagrelor who carry variations in the CYP2C19 and ABCB1 genes. The data were presented today at the European Society of Cardiology (ESC) congress in Stockholm, Sweden and simultaneously published in The Lancet.

Click here for more color.

---

Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!

You May Also Be Interested In

• Basilea participates in public-private collaboration to tackle antibiotic resistance
• DISH Network (DISH) Sued by Networks for 'Commercial Skipping' Feature
• Dow Chemical (DOW) Wins $2.16B in K-Dow Arbitration

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter